Introduction:

A few studies have been published on the central nervous system disorders (CNSD) after HSCT. Prospective studies including a control group are lacking.

Methods:

A prospective, observational study with infectious and non-infectious CNS disorders (iCNSD and niCNSD, respectively) after HSCT as primary objectives was conducted by the IDWP and the TCWP of EBMT. For each case patient (i.e. HSCT recipient with a CNSD), two control patients were allocated and analysed prospectively by applying the following selection criteria: not developing a CNSD until inclusion and surviving after HSCT the same time as the respective case patient until development of a CNSD (the inclusion date). Control patients were stratified by age (children vs adults), centre and HSCT type (allogeneic vs. autologous).

Results:

A total of 183 patients (61 patients with a CNSD, 122 controls) from 15 centres (8 countries) were included in this study between January 2021 and April 2024. Hereby, 57 patients with a CNSD (93%) underwent allogeneic and 4 patients (7%) autologous HSCT. Nineteen (31%) case patients were children (<18 years), and 42 (69%) adults (≥ 18 years).

Twenty-two patients (36%) had a proven/probable iCNSD, 28 patients (46%) had a proven/probable niCNSD and 11 patients (18%) had a possible infectious or non-infectious or unclassified CNSD. Forty-eight patients (79%) had an acute onset of the CNSD while onset was non-acute in 13 patients (21%). Human herpes virus 6 iCNSD was the most frequent proven/probable CNS infection (n=7) while infections by Toxoplasma spp. (n=5), Aspergillus spp. (n=3), bacteria (n=2), adenovirus (n=1) or different pathogens/unspecified infections (n=4) occurred less frequently. In patients with proven/probable niCNSD drug-induced changes were dominant (n=12) but vascular pathologies (bleeding, strokes etc., n=6) occurred also besides other (n=6, e.g. metabolic encephalopathy, posterior reversible encephalopathy syndrome or CNS relapse of the underlying disease) or unspecified causes (n=4). The median interval from HSCT to the CNSD onset was 31 days (range -1-153 days) for patients with proven/probable iCNSD (n=22) and 27 days (range -5-363 days) for patients with proven/probable niCNSD (n=28, p>0.05).

Magnetic resonance imaging (MRI) was done in 45/61 patients (74%). Abnormalities associated with the CNSD were described in 15/20 patients (75%) with proven/probable iCNSD and 12/19 (63%) of patients with proven/probable niCNSD (p>0.05).

A grade 3/4 eastern cooperative oncology group status at inclusion was more frequently present in CNSD (34/60 evaluable patients, 57%) than control patients (12/122 patients, 10%, p<0.001). Other variables such as median age, sex matching, HLA matching, disease status (71% complete remission in total), conditioning type, T cell depletion and stem cell source were comparable between cases and controls. Distribution of comorbidities was also largely comparable between both groups albeit a pre-existing CNS disease prior to HSCT was more frequent in the CNSD than in the control group (20% vs. 9%, p>0.05). Patients with a CNSD at inclusion were more frequently on ward (53/60 patients, 88%) than controls (72/122 patients, 59%, p<0.001). Among controls - none of them having a CNSD between HSCT and study inclusion - , 2/111 patients (1.8%, 95%-confidence interval (CI) 0.2-6.4%) developed a CNSD at day +100 after study inclusion and 9/117 patients (7.7%, 95%-CI 3.6-14.1%) at last follow-up.

Overall survival was lower (p<0.001) in patients with a CNSD - 85% (95%-CI 76-94%) at one month and 49% (95%-CI 35-63%) at 24 months - compared to controls - 99% (95%-CI 98-100%) and 82% (95%-CI 74-89%), respectively. Causes of death among cases were the CNSD (n=14/29, 48%), HSCT-related causes other than the CNSD (n=5, 17%) relapse/progression (n=3, 10%) or other reasons (n=7, 24%). Relapse/progression was the most frequent death cause among controls (n=13/18, 72%, p<0.001). At last follow-up, 14/22 patients (64%) with a proven/probable iCNSD had died, compared to 11/28 patients (39%) with a proven/probable niCNSD (p>0.05).

Conclusions:

CNSD represent a significant complication after HSCT. Hereby, non-infectious causes prevail over CNS infections. A pre-existing CNS disease prior to HSCT might be a risk factor for a CNS complication after HSCT. Patients with a CNSD after HSCT have a reduced overall survival with the CNSD itself being the main cause of death.

Disclosures

Schmidt-Hieber:MSD: Speakers Bureau; Amgen: Speakers Bureau; Sanofi-Aventis: Speakers Bureau; Stem Line: Honoraria; MICE: Honoraria; NewConceptOncology: Honoraria; Shionogi: Speakers Bureau; BMS: Speakers Bureau. Einsele:Amgen: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Sanofi: Honoraria; Celgene/Bristol-Meyers Squibb: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Janssen: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Novartis: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Takeda: Honoraria, Membership on an entity's Board of Directors or advisory committees; BMS: Honoraria. Peffault De Latour:pfizer: Consultancy, Honoraria, Research Funding; soby: Consultancy, Honoraria, Research Funding; novartis: Consultancy, Honoraria, Research Funding; alexion: Consultancy, Honoraria, Research Funding. Biffi:Eusa Pharma: Consultancy; Astellas: Speakers Bureau; Bluebird: Speakers Bureau; Medac Pharma: Consultancy, Speakers Bureau; Iqone (Clinigen): Consultancy; Gilead: Consultancy; Novartis: Consultancy; Amgen: Consultancy, Speakers Bureau; Bayer: Consultancy; Takeda: Consultancy. Czyzewski:AstraZeneca: Honoraria; MSD: Honoraria; Gilead: Honoraria; Theracos: Honoraria. Martínez-Lopez:BMS: Consultancy, Honoraria; Pfizer: Consultancy, Honoraria, Research Funding; Janssen: Consultancy, Honoraria, Research Funding; Kite: Consultancy, Honoraria; Amgen: Consultancy, Honoraria; Roche: Consultancy, Honoraria; Incity: Research Funding. Averbuch:MSD: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau. Styczynski:Roche: Other: Travel Grant; Medac: Other: Travel Grant; Sanofi: Honoraria, Speakers Bureau; AstraZeneca: Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Novartis: Honoraria; Gilead: Honoraria, Other: travel grant, Speakers Bureau; MSD: Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Travel Grant, Speakers Bureau; AbbVie: Other: Travel Grant; Chiesi: Membership on an entity's Board of Directors or advisory committees; Pfizer: Membership on an entity's Board of Directors or advisory committees. De La Camara:MSD: Membership on an entity's Board of Directors or advisory committees.

This content is only available as a PDF.
2024
Sign in via your Institution